Erythropoietin claims monitoring policy: implications for clinical practice. Nephrology nursing journal : journal of the American Nephrology Nurses' Association. [Nephrol Nurs J] Journal article

Title	Erythropoietin claims monitoring policy: implications for clinical practice.
Author(s)	Messana T
Institution	St. Joseph Hospital Renal Services, Orange, CA, USA.
Source	Nephrol Nurs J 2006 Mar-Apr; 33(2):209-13, 222; quiz 214-5.
MeSH	Anemia Documentation Drug Costs Drug Utilization Epoetin Alfa Erythropoietin Hematinics Hemoglobins Humans Insurance Claim Reporting Kidney Failure, Chronic Organizational Policy Patient Selection Practice Guidelines Reimbursement Mechanisms Renal Dialysis Research Support, Non-U.S. Gov't Risk Factors Total Quality Management United States United States Centers for Medicare and Medicaid Services
Abstract	The revised erythropoietin claims monitoring policy that will govern reimbursement by the Centers for Medicare & Medicaid Services for Epoettin alfa and darbepoetin alfa administered to patients on dialysis takes effect on April 1, 2006. The new policy provides several significant improvements that should enhance clinicians' ability to manage anemia rationally. However, several aspects of the new policy are ambiguous and will require further clarification and ongoing evaluation to determine the effect on practice patterns and clinical outcomes.
Language	eng
Pub Type(s)	Journal Article Review
PubMed ID	16613415

Advertise on this site.